Machine Learning In Cancer Clinical Trials Articles Big Data

It is also being used to identify the drugs that particular patients are more likely to respond to, most recently with Berg, who are hoping to identify the biological makeup of cancer patients who are likely to respond best to their drugs. Berg CEO and co-founder Niven Narain is confident of its success - 'With use of Berg's Interrogative Biology platform, we will be applying our precision medicine approach where output from this trial will allow us to match patients to this given combination based on their biological profile.'